Safran Howard, Rathore Ritesh
The Brown University Oncology Group, Department of Medicine, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA.
Crit Rev Oncol Hematol. 2002 Jul;43(1):57-62. doi: 10.1016/s1040-8428(01)00184-6.
Paclitaxel and concurrent radiation (paclitaxel/RT) have been evaluated by the Brown University Oncology Group (BrUOG) and the Radiation Therapy Oncology Group (RTOG) in phase I and II studies for patients with locally advanced pancreatic cancer. The dose limiting toxicities were abdominal pain within the radiation field, nausea and anorexia. The phase II Brown University study, utilizing paclitaxel 50 mg/m(2) per week for 6 weeks with 50.4 Gy radiation, demonstrated modest locoregional activity and acceptable toxicity. The median and 1-year survival of paclitaxel/RT in the RTOG phase II study suggests an improvement over previous RTOG studies of fluorouracil (5-FU) and radiation. The addition of gemcitabine to paclitaxel and radiation has also demonstrated promising preliminary activity and a phase II study by the RTOG is being initiated.
布朗大学肿瘤学组（BrUOG）和放射治疗肿瘤学组（RTOG）已在Ⅰ期和Ⅱ期研究中对局部晚期胰腺癌患者使用紫杉醇与同步放疗（紫杉醇/放疗）进行了评估。剂量限制性毒性为放射野内的腹痛、恶心和厌食。布朗大学的Ⅱ期研究，采用每周50mg/m²的紫杉醇，共6周，并联合50.4Gy的放疗，显示出适度的局部区域活性和可接受的毒性。RTOGⅡ期研究中紫杉醇/放疗的中位生存期和1年生存率表明，相较于RTOG之前关于氟尿嘧啶（5-FU）与放疗的研究有所改善。在紫杉醇和放疗基础上加用吉西他滨也已显示出有前景的初步活性，RTOG正在启动一项Ⅱ期研究。
